DOUBLE BLIND PLACEBO STUDY OF ACUTE HEMODYNAMIC BMS 193884

急性血流动力学 BMS 193884 的双盲安慰剂研究

• 批准号: 6264237
• 负责人: EDWARD M GILBERT
• 金额: $ 0.16万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264237
• 关键词: clinical research; clinical trial phase I; congestive heart failure; dosage; drug screening /evaluation; endothelin; hormone receptor; human subject; human therapy evaluation; vascular smooth muscle; vasoconstriction; vasodilators

This category D study, sponsored by Bristol Meyer-Squibb, has been completed. Endothelins represent a family of vasoactive peptides which have a prominent role in the regulation of vascular tone and blood pressure. Endothelins also play a role in conditions associated with chronic vasoconstriction, such as congestive heart failure. Receptors for endothelins exist on smooth muscle cells of vascular walls, and the drug under study, BMS-193884, is a selective antagonist for one of the key endothelin receptors. A safe therapeutic dose range was defined in this study, and the drug also proved efficacious in treating heart failure. Data collected has been forwarded to the drug company sponsor for final analysis and publication.

由Bristol Meyer-Squibb赞助的D类研究已完成。 内皮蛋白代表一个血管活性肽家族，在血管张力和血压调节中具有重要作用。 内皮素在与慢性血管收缩相关的疾病中也发挥作用，例如充血性心力衰竭。 内皮蛋白的受体存在于血管壁的平滑肌细胞上，而正在研究的药物BMS-193884是一个关键内皮素受体之一的选择性拮抗剂。在这项研究中定义了安全的治疗剂量范围，该药物也证明可以有效治疗心力衰竭。 收集到的数据已转发给制药公司赞助商进行最终分析和出版。